OVERVIEW
This policy documents the coverage determination for Cryosurgical Ablation of Hepatic Tumors. Cryosurgical ablation involves the use of extreme cold to destroy abnormal tissue. Liquid nitrogen or argon gas is circulated through a hollow probe that is placed in contact with the tissue to be destroyed.

PRIOR AUTHORIZATION
Not Applicable

POLICY STATEMENT
BlueCHiP for Medicare and Commercial

Cryosurgical ablation of either primary or metastatic tumors in the liver is considered not medically necessary as there is insufficient evidence to draw conclusions about its effectiveness.

MEDICAL CRITERIA
None

BACKGROUND
Hepatic tumors can arise either as primary liver cancer or by metastasis to the liver from other tissues. Local therapy for hepatic metastasis is indicated only when there is no extra hepatic disease, which rarely occurs for patients with primary cancers other than colorectal carcinoma or certain neuroendocrine malignancies. At present, surgical resection with tumor-free margins or liver transplantation represents the only treatments with curative potential. For liver metastases from colorectal cancer, post-surgical adjuvant chemotherapy has been reported to decrease recurrence rates and prolong time to recurrence. However, most hepatic tumors are unresectable at diagnosis, due either to their anatomic location, size, number of lesions, or underlying liver reserve. Combined systemic and hepatic arterial chemotherapy may increase disease-free intervals for patients with hepatic metastases from colorectal cancer, but apparently is not beneficial for those with unresectable hepatocellular carcinoma.

Cryosurgical ablation (hereafter, cryosurgery) involves the use of extreme cold to destroy abnormal tissue. Liquid nitrogen or argon gas is circulated through a hollow probe that is placed in contact with the tissue to be destroyed. A mass of ice crystals forms around the tip of the probe and freezes nearby cells. After cryosurgery, the ablated tissue is absorbed by the body. Cryosurgery may be performed as an open surgical technique or as a closed procedure under laparoscopic or ultrasound guidance.

Cryosurgical ablation therapy for unresectable liver tumors is being studied yet there is a lack of sufficient rigorous data to draw conclusions about the impact of cryosurgical ablation on clinical outcomes compared to existing alternatives for those with colorectal cancer metastatic to the liver. The MEDLINE search did not identify any articles that provide additional relevant data related to other applications of cryoablation for liver tumor, such as hepatocellular carcinoma. Overall, the data for cryosurgical ablation of liver tumors is of lower quality than the data for radiofrequency ablation of liver tumors. Therefore, this technique is considered investigational.
COVERAGE
Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage, Subscriber Agreement for applicable Services Not Medically Necessary coverage/benefits.

CODING
Blue CHiP for Medicare and Commercial

The following cryosurgery CPT codes are considered not medically necessary:

47371 47381

RELATED POLICIES
None

PUBLISHED
Provider Update  Aug 2011
Provider Update  Dec 2010
Provider Update  May 2008

REFERENCES
Charles H. Scudmore, MD, FRCS, FACS, Emma J. Patterson BSc(Hon), MD, AM, James Chapiro, MB, FRCS, and Andrzej K. Buczkowski, MD, Live Tumor Ablation Techniques, Investigative Surgery, Volume 10: 157-164 July/August 1997.

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.